Possible new druggable targets for the treatment of nephrosis. Perhaps we should find them in caveolea?

Current Opinion in Pharmacology

Volumn 9, Issue 2, 2009, Pages 132-138

  van Dokkum, Richard PE ^a   Buikema, Hendrik ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

CARDIOVASCULAR DISEASE; CAVEOLEA; CELL MEMBRANE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY FIBROSIS; KIDNEY INJURY; MICROALBUMINURIA; NEPHROSIS; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENOVASCULAR HYPERTENSION; REVIEW;

ALBUMINURIA; ANIMALS; ANTIOXIDANTS; CAVEOLAE; CAVEOLINS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; FIBROSIS; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; NEPHROSIS;

EID: 62349089173     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.12.008     Document Type: Review

References (51)

1. Charlesworth J.A., Gracey D.M., and Pussell B.A. Adult nephrotic syndrome: non-specific strategies for treatment. Nephrology 3 (2008) 45-50
2. Brenner B.M., Goldszer R.C., and Hostetter T.H. Glomerular response to renal injury. Contrib Nephrol 33 (1982) 48-66
3. Dunn B.R., Anderson S., and Brenner B.M. The hemodynamic basis of progressive renal disease. Semin Nephrol 6 (1986) 122-138
4. Remuzzi G., and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339 (1998) 1448-1456
5. Abbate M., Benigni A., Bertani T., and Remuzzi G. Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 14 (1999) 304-312
6. Fogo A.B. Mechanisms of progression of chronic kidney disease. Pediatr Nephrol 22 (2007) 2011-2022
7. Brosius III F.C. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 9 (2008) 245-254
8. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 32 (1989) 219-226
9. Amann K., Wanner C., and Ritz E. Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol 17 (2006) 2112-2119
10. Stehouwer C.D., and Smulders Y.M. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol 17 (2006) 2106-2111
11. de Zeeuw D., Parving H.H., and Henning R.H. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 17 (2006) 2100-2105
12. Fogo A.B. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 75 (2000) S15-S21
13. Toto R.D. Treatment of hypertension in chronic kidney disease. Semin Nephrol 25 (2005) 435-439
14. Wenzel R.R. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 65 Suppl 2 (2005) 29-39
15. Ruzicka M., Burns K.D., Culleton B., and Tobe S.W. Canadian Hypertension Education Program. Treatment of hypertension in patients with nondiabetic chronic kidney disease. Can J Cardiol 23 (2007) 595-601
16. Orth S.R., Weinreich T., Bönisch S., Weih M., and Ritz E. Angiotensin II induces hypertrophy and hyperplasia in adult human mesangial cells. Exp Nephrol 3 (1995) 23-33
17. Wolf G., and Neilson E.G. Angiotensin II as a renal growth factor?. J Am Soc Nephrol 3 (1993) 1531-1540
18. Oikawa T., Freeman M., Lo W., Vaughan D.E., and Fogo A. Modulation of plasminogen activator inhibitor-1 (PAI-1) in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 51 (1997) 164-172
19. Ketteler M., Noble N.A., and Border W.A. Transforming growth factor-b and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?. Ann Rev Physiol 57 (1995) 279-295
20. Deelman L., and Sharma K. Mechanisms of kidney fibrosis and the role of anti-fibrotic therapy. Cur Op Nephrol Hypertens 18 (2009) 85-90
21. Liu-Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 69 (2006) 213-217. Mini review highlighting cellular and molecular pathways leading to renal fibrosis, and in particular detailing the fibrogenic action of TGF-β/Smad signalling as a novel target for therapeutic strategies in renal fibrosis.
22. Wühl E., and Schaefer F. Therapeutic strategies to slow chronic kidney disease progression. Pediatr Nephrol 23 (2008) 705-716
23. Fukami K., Yamagishi S., Ueda S., and Okuda S. Novel therapeutic targets for diabetic nephropathy. Endocr Metab Immune Disord Drug Targets 7 (2007) 83-92. Comprehensive review describing the interaction between metabolic and hemodynamic pathways in diabetic nephropathy, and providing an overview of interfering drugs currently used clinically as a first-line treatment or under current clinical development for the treatment of diabetic nephropathy.
24. Camici M. Renal glomerular permselectivity and vascular endothelium. Biomed Pharmacother 59 (2005) 30-37
25. Stam F., van Guldener C., Becker A., Dekker J.M., Heine R.J., Bouter L.M., and Stehouwer C.D.A. Endothelial dysfunction contributes to renal function-associated cardiovascular mortality in a population wit mild renal insufficiency: the Hoorn study. J Am Soc Nephrol 61 (2006) 586-590
26. Zoccali C. The endothelium as a target in renal diseases. J Nephrol 20 Suppl 12 (2007) S39-S44
27. Schiffrin E.L., Lipman M.L., and Mann J.F.E. Chronic kidney disease. Effects of the cardiovascular system. Circulation 116 (2007) 85-97
28. Wu-Wong J.R. Endothelial dysfunction and chronic kidney disease: treatment options. Curr Opin Investig Drugs 9 (2008) 970-982
29. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Luft F.C., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293 (2001) 2449-2452
30. Xu Y., Henning R.H., van der Want J.J.L., van Buiten A., van Gilst W.H., and Buikema H. Disruption of endothelial caveolae is associated with impairment of both NO- as well as EDHF in acetylcholine-induced relaxation depending on their relative contribution in different vascular beds. Life Sci 80 (2007) 1678-1685
31. Frank P.G., Woodman S.E., Park D.S., and Lisanti M.P. Caveolin, caveolae, and endothelial cell function. Arterioscler Thromb Vasc Biol 23 (2003) 1161-1168
32. Rizzo V., Sung A., and Schnitzer J.E. Rapid mechanotransduction in situ at the luminal cell surface of the microvascular endothelium and its caveolae. J Biol Chem 273 (1998) 26323-26329
33. Li C., and Xu Q. Mechanical stress-initiated signal transduction in vascular smooth muscle cells in vitro and in vivo. Cell Signal 19 (2007) 881-891
34. 1-receptor and EGF-receptor function. Eur J Heart Fail 2009, in press. Animal study providing evidence that decreased vascular smooth muscle cell caveolae number may be implicated in enhanced myogenic response in small mesenteric arteries of rats with experimentally induced heart failure by affecting constitutive EGF-receptor activity. The results of this study suggest a mechanism of derailments in vasomotor autoregulation as a consequence of caveolar changes in pathophysiological conditions via basic alterations in receptor function. It may challenge future studies for investigation of alterations in caveolar changes underlying impaired autoregulation in renal vasculature in pathophysiological conditions of kidney disease.
35. Albinsson S., Shakirova Y., Rippe A., Baumgarten M., Rosengren B.I., Rippe C., Hallmann R., Hellstrand P., Rippe B., and Swärd K. Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice. Am J Physiol Regul Integr Comp Physiol 293 (2007) R1222-R1231
36. ••] in that both studies underline the importance of caveolae involved in normal autoregulation of vascular tone on the one hand. While on the other hand, the discrepancy between both studies at the same time underlines the importance of caveolae as a structural entity as well as presence of cav-1 as a direct regulatory protein. Above all, however, such studies should challenge future studies for investigation of alterations in caveolar changes underlying impaired autoregulation in renal vasculature in pathophysiological conditions of kidney disease.
37. Van Dokkum R.P., Sun C.W., Provoost A.P., Jacob H.J., and Roman R.J. Altered renal hemodynamics and impaired myogenic responses in the fawn-hooded rat. Am J Physiol Regul Integr Comp Physiol 276 (1999) R855-R863
38. Xu Y., Buikema H., van Gilst W.H., and Henning R.H. Caveolae and endothelial dysfunction: filling the caves in cardiovascular disease. Eur J Pharmacol 585 (2008) 256-260
39. Robert B., and Abrahamson D.R. Control of glomerular capillary development by growth factors/receptor kinases. Pediatr Nephrol 16 (2001) 294-301
40. Sugimoto H., Hamano Y., Charytan D., Cosgrove D., Kieran M., Sudhakor A., and Kalluri R.I. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFit-1) induces proteinuria. J Biochem 278 (2003) 12605-12608
41. Satchell S.C., Anderson K.L., and Mathieson P.W. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 15 (2004) 566-574
42. De Laurentiis A., Donovan L., and Arcaro A. Lipid rafts and caveolae in signaling by growth factor receptors. Open Biochem J 1 (2007) 12-32
43. ••,38].
44. Lin M.I., Yu J., Murata T., and Sessa W.C. Caveolin-1 deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res 67 (2007) 2849-2856
45. Chen J., Braet, Brodsky, Weinstein T., Romanov V., Noiri E., and Goligorsky M.S. VEGF-induced mobilization of caveolae and increase in permeability of endothelial cells. Am J Physiol Cell Physiol 282 (2002) C1053-C1063
46. Ushio-Fukai M. Compartmentalization of Redox Signalling through NADPH Oxidase-derived ROS. Antioxid Redox Signal (2008) Epub ahead of print
47. Peng F., Zhang B., Wu D., Ingram A.J., Gao B., and Krepinsky J.C. TGFβ-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am J Physiol Renal Physiol 295 (2008) F153-F164. Using primary rat mesangial cells, the authors show the requirement of caveolae and caveolin-1 interaction with RhoA in TGF-β-induced fibronectin upregulation. Such results may highlight caveolae as a potential interventional target for the treatment of fibrotic renal disease.
48. Frank P.G., Pavlides S., and Lisanti M.P. Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res 335 (2009) 41-47
49. Schubert W., Frank P.G., Woodman S.E., Hoyogo H., Cohen D.E., Chow C.W., and Lisanti M.P. Microvascular hyperpermeability in caveolin-1 (-/-) knockout mice: treatment with a specific nitric-oxide synthase inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 277 (2002) 40091-40098
50. Drexler H., Hayoz D., Munzel T., Hornig B., Just H., Brunner H.R., and Zelis R. Endothelial dysfunction in chronic congestive heart failure. Am J Cardiol 69 (1992) 1596-1601
51. Goligorsky M.S., Hong L., Brodsky S., and Chen J. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am J Physiol Renal Physiol 52 (2002) F1-F10